|
Irradiation of blood products: one year experience in Tehran Blood Transfusion Center
|
M. Zadsar   , H. Sadegh , M. Naseranipoor , B. Haji Beigi , S.M. Mirrezaie |
|
|
| Keywords: Graft-Versus-Host Disease, Transfusion Reaction, prevention |
|
|
Full-Text [PDF 231 kb]
(3927 Downloads)
| Abstract (HTML) (13785 Views)
|
Type of Study: Research |
Subject:
Blood transfusion medicine
Published: 2013/10/5
|
|
|
|
|
|
|
Full-Text: (6209 Views) |
References:
14- sohi , Jacobs. Tranafusion associated GVHD InMurphy JB. The effect of adult chicken organ grafts on the chick embryo. J Exp Med 1916; 24(1): 1-5.- Danchakoff V. Equivalence of different hematopoietic anlages (by method of stimulation of their stem cells). I. Spleen. Am J Anat 1916; 20(3): 255-327.
- Mathe G, Bernard J, de Vries MJ, Schwarzenberg L, Larrieu MJ, Amiel JL, et al. New trials with homologous bone marrow grafts after total irradiation in children with acute leukemia in remission. The problem of the secondary syndrome in man. Rev Hematol 1960; 15: 115-61. [Article in French]
- von Fliedner V, Higby DJ, Kim U. Graft-versus-host reaction following blood product transfusion. Am J Med 1982; 72(6): 951-61.
- Hathaway WE, Githens JH, Blackburn WR, Fulginiti V, Kempe CH. Aplastic anemia, histiocytosis and erythrodermia in immunologically deficient children. Probable human runt disease. N Engl J Med 1965; 273(18): 953-8.
- Brubaker DB. Human posttransfusion graft-versus-host disease. Vox Sang 1983; 45(6): 401-20.
- Leitman SF, Holland PV. Irradiation of blood products.
Indications and guidelines. Transfusion 1985; 25(4): 293-303.
- Williamson LM, Stainsby D, Jones H, Love E, Chapman CE, Navarrete C, et al. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease. Transfusion 2007; 47(8): 1455-67.
- Otsuka S, Kunieda K, Hirose M, Takeuchi H, Mizutani Y, Nagaya M, et al. Fatal erythroderma (suspected graft-versus-host disease) after cholecystectomy. Retrospective analysis. Transfusion 1989; 29(6): 544-8.
- Sakakibara T, Juji T. Post-transfusion graft-versus-host disease after open heart surgery. Lancet. 1986; 2(8515): 1099.
- Thaler M, Shamiss A, Orgad S, Huszar M, Nussinovitch N, Meisel S, et al. The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery. N Engl J Med 1989; 321(1): 25-8.
- Utter GH, Reed WF, Lee TH, Busch MP. Transfusion-associated microchimerism. Vox Sang 2007; 93(3): 188-95.
- Valerius NH, Johansen KS, Nielsen OS, Platz P, Rosenkvist J, Sørensen H. Effect of in vitro X-irradiation on lymphocyte and granulocyte function. Scand J Haematol 1981; 27(1): 9-18.
- Drobyski W, Thibodeau S, Truitt RL, Baxter-Lowe LA, Gorski J, Jenkins R, et al. Third-party-mediated graft rejection and graft-versus-host disease after T-cell-depleted bone marrow transplantation, as demonstrated by hypervariable DNA probes and HLA-DR polymorphism. Blood 1989; 74(6): 2285-94.
- Rivet C, Baxter A, Rock G. Potassium levels in
irradiated blood. Transfusion 1989; 29(2): 185.
- Strauss RG. Routinely washing irradiated red cells before transfusion seems unwarranted. Transfusion 1990; 30(8): 675-7.
- Anderson KC, Goodnough LT, Sayers M, Pisciotto PT, Kurtz SR, Lane TA, et al. Variation in blood component irradiation practice: implications for prevention of transfusion-associated graft-versus-host disease. Blood 1991; 77(10): 2096-102.
- Janatpour K, Denning L, Nelson K, Betlach B, Mackenzie M, Holland P. Comparison of X-ray vs. gamma irradiation of CPDA-1 red cells. Vox Sang 2005; 89(4): 215-9.
- Roback J, Rae Combs M, Grossman B, Hillyer Ch. Technical Manual. 16th ed. Bethesda: AABB; 2008. p. 213.
- Treleaven J, Gennery A, Marsh J, Norfolk D, Page L, Parker A, et al. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Br J Haematol 2011; 152(1): 35-51.
- Annual shot report 2011. UK: Serious Hazards of Transfusion; 2012. Available from: http://www. shotuk. org/ wp-content/ uploads/ 2012/ 07/ SHOT-ANNUAL -REPORT_ FinalWebVersionBookmarked_ 2012_06_22.pdf.
- Henry BJ, Davey FR, Herman Ch, McPherson RA. Clinical Diagnosis and Management by Laboratory Methods. 21st ed. New York: Saunders; 2007. p. 669-81.
- Mintz PD, Wehrli G. Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products. Bone Marrow Transplant 2009; 44(4): 205-11.
|
Sci J Iran Blood Transfus Organ 2013; 10(3): 312-318
|
Irradiation of blood products: one year experience
in Tehran Blood Transfusion Center
Zadsar M.1,2, Sadegh H.1,2, Naseranipoor M.1,2, Haji Beigi B.1, Mirrezaie S.M.1,2,3
1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
2Tehran Regional Educational Blood Transfusion Center, Tehran, Iran
3Research Center for Health Related Social and Behavioral Sciences, Shahroud University of Medical Sciences, Shahroud, Iran
Abstract
Background and Objectives
Pre-transfusion inactivation of donor T-cells by irradiation is the method of choice for prevention of TA-GVHD. This study reviewed the usage of irradiated products in one year period in Tehran Blood Transfusion Center.
Materials and Methods
There were 1333 requests for irradiated blood products to be evaluated. The data including the quantity and type of irradiated products, patients’ age and indications were gathered. Descriptive statistical analysis was performed by SPSS 18 software.
Results
The requested irradiated products in the one-year period of time include platelets (71.3%), packed RBCs (28.1%), FFP (0.4%), paediatric bags (0.2%), and whole blood (0.1%). The age groups of patients having received irradiated products were adults (59.6%), children (25.9%), infants (6.5%), and neonates (3.3%). Indications of prescription consist of leukaemia/lymphoma and Hodgkin (49.6%), allogeneic and autologous bone marrow transplantation (17.7%), immunosuppressive therapy (9.6%), congenital immunodeficiency (8.6%), premature birth (7.6%), aplastic anaemia (6.5%), relatives designated donation (0.3%), and HLA matched plateletphaeresis (0.1%). The increasing trend in the quantity of requests of irradiated products and requesting hospitals was observed.
Conclusions
It is recommended that a higher number of hospitals and their staff be informed about irradiated products and their indications and the roles they have on the prevention of TA-GVHD.
Key words: Graft-Versus-Host Disease, Transfusion Reaction, prevention
Received: 16 Aug 2011
Accepted:23 Feb 2013
Correspondence: Zadsar M., MD. Specialist in Infectious Diseases and Tropical Medicine. Assistant Professor of Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine and Tehran Regional Educational Blood Transfusion Center.
P.O.Box: 14155-1565, Tehran, Iran. Tel: (+9821) 8898997; Fax: (+9821) 88963034
E-mail: maryam_zad@yahoo.com
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Zadsar M, Sadegh H, Naseranipoor M, Haji Beigi B, Mirrezaie S. Irradiation of blood products: one year experience in Tehran Blood Transfusion Center. Sci J Iran Blood Transfus Organ 2013; 10 (3) :312-318 URL: http://bloodjournal.ir/article-1-801-en.html
|
.jpg)
.png)
